Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?
Ann Rheum Dis
.
2019 Apr;78(4):e27.
doi: 10.1136/annrheumdis-2018-213332.
Epub 2018 Mar 9.
Authors
Esther Mossel
1
,
Konstantina Delli
2
,
Suzanne Arends
1
,
Erlin A Haacke
1
3
,
Bert van der Vegt
3
,
Jolien F van Nimwegen
1
,
Alja J Stel
1
,
Fred K L Spijkervet
2
,
Arjan Vissink
2
,
Frans G M Kroese
1
,
Hendrika Bootsma
1
Affiliations
1
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.
2
Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
3
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
PMID:
29523521
DOI:
10.1136/annrheumdis-2018-213332
No abstract available
Keywords:
sjøgren’s syndrome; treatment; ultrasonography.
Publication types
Letter
Comment
MeSH terms
Double-Blind Method
Humans
Rituximab
Salivary Glands
Sjogren's Syndrome*
Ultrasonography
Substances
Rituximab